Leukine sargramostim: Completed Phase II enrollment

SCH completed patient enrollment in the double-blind, placebo-controlled, U.S. and Canadian Phase II NOVEL 2 trial. Patients are receiving daily subcutaneous Leukine or placebo for up to 22 weeks. ...